ライフサイエンスコーパス: thyroid

1 a direct and selective effect of ICM on the thyroid.

2 oma, we characterized stromal cells from the thyroid.

3 issues, with specifically high uptake in the thyroid.

4 to a reduction in radiotracer uptake by the thyroid, accompanied by a dramatic reduction in NIS prot

5 udied in multiple cancer types, particularly thyroid and colorectal, but their combined role in tumou

6 Thyroid and glucocorticoid hormones are critical for hea

7 esults suggest a permissive role of combined thyroid and glucocorticoid hormones during the cardiac d

8 f (99m)Tc-pertechnetate uptake in both mouse thyroid and mouse salivary glands.

9 ies in transcriptomic regulation between the thyroid and other tissues despite large differences in a

10 ure death in mice, we assayed for changes in thyroid and pituitary hormones.

11 nd (123)I in 2 NIS-expressing mouse tissues, thyroid and salivary glands.

12 Active iodide (I(-)) transport in both the thyroid and some extrathyroidal tissues is mediated by t

13 positive selection, ranging from <1/tumor in thyroid and testicular cancers to >10/tumor in endometri

14 yroid cancer histotypes compared with normal thyroid and that its expression levels correlate with T

15 tem/stromal cells (MSCs) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

16 d in 5 patients (0.7%; 2 lung, 1 lymphoma, 1 thyroid, and 1 base of tongue).

17 ancers from prostate, breast, colon, kidney, thyroid, and lymphoid tissues as well as NETs as referen

18 Thyroid- and TH-associated upstream regulators as well a

19 Additionally, thyroid antibodies have been associated with other neona

20 Thyroid antibodies in pregnant women with normal functio

21 cross therapeutic targets-ranging between 0 (thyroid, ascites) and 8.48 months (breast cancers)-and w

22 Various thyroid-associated diseases and functions were inferred

23 to 7, with a score of >/=3 indicating active thyroid-associated ophthalmopathy) and a reduction of 2

24 n the past two decades, and revised American Thyroid Association guidelines on this topic were publis

25 Consequently, the 2015 American Thyroid Association guidelines strongly recommend invest

26 This Review explores the association between thyroid autoimmunity and complications during and after

27 Pathogenic mechanisms in CSU patients with thyroid autoimmunity may include IgE against autoantigen

28 uding CSU is more prevalent in patients with thyroid autoimmunity than in controls (weak evidence).

29 pituitary-adrenal and hypothalamic-pituitary-thyroid axes, as well as a rise in systolic blood pressu

30 to disruption of the hypothalamic-pituitary-thyroid axis with resistance to TH, while mutation of TR

31 0 knock-out mice as a new model for studying thyroid biology.

32 Ga-DOTATATE uptake in the liver, spleen, and thyroid but did not compromise tracer uptake in residual

33 f circulating T3 is directly released by the thyroid, but in states of hyperactivation of thyroid-sti

34 yroid mice displayed oxidative stress in the thyroid, but not in the brown adipose tissue or liver.

35 thologic evaluation, 47 (36%) had incidental thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocy

36 primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [95% CI, 4.0

37 Anaplastic thyroid cancer (ATC) is a rare malignancy that accounts

38 Patients with metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroi

39 everal susceptibility loci of differentiated thyroid cancer (DTC) were identified by previous genome-

40 ncer (AJCC) TNM staging system for medullary thyroid cancer (MTC).

41 lti-generation CS-like family with papillary thyroid cancer (PTC), applying a combined linkage-based

42 ctor in the risk stratification of papillary thyroid cancer (PTC), but whether this is generally appl

43 ) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

44 rine model of Braf(V600E) -induced papillary thyroid cancer (PTC).

45 cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with radioactive io

46 ents undergoing total thyroidectomy, 47% had thyroid cancer and 53% benign disease.

47 us on radioiodine therapy for differentiated thyroid cancer and peptide receptor radionuclide therapy

48 s of persons treated for well-differentiated thyroid cancer and persons with no surgery or surveillan

49 in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferentiation tre

50 The incidence of detected thyroid cancer cases has been increasing in the United S

51 nctional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against

52 extracellular superoxide dismutase (SOD3) in thyroid cancer cell lines although according to recent d

53 eptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels

54 e in RAI-refractory papillary and follicular thyroid cancer cell lines.

55 essential for proliferation and survival of thyroid cancer cells harboring PI3K-activating mutations

56 p27 expression and potentiated apoptosis in thyroid cancer cells while not affecting survival in nor

57 er a 2-fold increased prevalence (OR 2.7) of thyroid cancer compared to PTEN-associated CS but 50% de

58 CS but 50% decreased prevalence (OR 0.54) of thyroid cancer compared to SDHx-associated CS.

59 hether the increasing incidence of papillary thyroid cancer has been related to thyroid cancer mortal

60 Most cases of thyroid cancer have a good prognosis; the 5-year surviva

61 cer is the second most common differentiated thyroid cancer histological type and has been overshadow

62 O1 expression is significantly higher in all thyroid cancer histotypes compared with normal thyroid a

63 roid cancer screening and treatment of early thyroid cancer in asymptomatic adults to inform the US P

64 e on the benefits and harms of screening for thyroid cancer in asymptomatic adults, the diagnostic ac

65 insurance had lower thyroidectomy rates for thyroid cancer in Massachusetts and the control states c

66 In 2013, the incidence rate of thyroid cancer in the United States was 15.3 cases per 1

67 nt with a true increase in the occurrence of thyroid cancer in the United States.

68 Annual percent changes in age-adjusted thyroid cancer incidence and incidence-based mortality r

69 Thyroid cancer incidence has increased substantially in

70 Papillary thyroid cancer incidence increased for all SEER stages a

71 Thyroid cancer incidence increased, on average, 3.6% per

72 To our knowledge, thyroid cancer incidence is increasing faster than any o

73 Thyroid cancer is a major component cancer of Cowden syn

74 Thyroid cancer is common, yet the sequence of alteration

75 rmined that the net benefit of screening for thyroid cancer is negative.

76 Thyroid cancer is the most common cancer in Korea.

77 Follicular thyroid cancer is the second most common differentiated

78 but their clinicopathologic significance in thyroid cancer is unclear.

79 Thyroid cancer morbidity and mortality, test accuracy to

80 papillary thyroid cancer has been related to thyroid cancer mortality trends.

81 good prognosis; the 5-year survival rate for thyroid cancer overall is 98.1%.

82 advances are yielding critical insights into thyroid cancer pathogenesis, which are being leveraged f

83 points were examined retrospectively for 65 thyroid cancer patients, referred to determine (131)I up

84 explain the clinically observed decrease in thyroid cancer prevalence in patients with co-existent P

85 ancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist t

86 eview the benefits and harms associated with thyroid cancer screening and treatment of early thyroid

87 s (n = 5894) directly addressed the harms of thyroid cancer screening, none of which suggested any se

88 sociated methylation differences between the thyroid cancer subtypes were linked to differential gene

89 e to distinguish between two uterine and two thyroid cancer subtypes.

90 d a gene expression signature from zebrafish thyroid cancer that is predictive of disease-free surviv

91 F and PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient outc

92 ensively review the literature on follicular thyroid cancer to provide an evidence-based guide to the

93 the association of insurance expansion with thyroid cancer treatment using the 2006 Massachusetts he

94 Change in the thyroidectomy rate for thyroid cancer treatment was the primary outcome evaluat

95 he 2006 Massachusetts health care reform and thyroid cancer treatment, and participants were controll

96 scans of 5 subjects with recently diagnosed thyroid cancer were acquired before surgery for up to 4

97 se that undergoes rearrangement in papillary thyroid cancer).

98 , test accuracy to detect thyroid nodules or thyroid cancer, and harms resulting from screening (incl

99 nome-wide association study of non-medullary thyroid cancer, including in total 3,001 patients and 28

100 y thyroid carcinoma (PTC), the most frequent thyroid cancer, is characterized by low proliferation bu

101 internal radiation dosimetry, in humans with thyroid cancer, of (18)F-tetrafluoroborate ((18)F-TFB),

102 ter than small, given the relative rarity of thyroid cancer, the apparent lack of difference in outco

103 wed by its more common counterpart-papillary thyroid cancer-despite its unique biological behaviour a

104 Papillary thyroid cancer-specific mortality for cases with both mu

105 Papillary thyroid cancer-specific mortality occurred in 4 of 629 p

106 This study aimed to assess the overall and thyroid cancer-specific survival in a large cohort of pa

107 , sex, primary malignancy, overall survival, thyroid cancer-specific survival, FNA, and histopatholog

108 SF3 may be involved in the predisposition of thyroid cancer.

109 creased access to the surgical management of thyroid cancer.

110 ase-free survival in patients with papillary thyroid cancer.

111 %) died from incidentally detected medullary thyroid cancer.

112 rce (USPSTF) recommendation on screening for thyroid cancer.

113 sortilin as potential therapeutic targets in thyroid cancer.

114 ct of insurance statuses on the treatment of thyroid cancer.

115 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.

116 ng (including overdiagnosis) or treatment of thyroid cancer.

117 es for future studies of the pathogenesis of thyroid cancer.

118 ts and harms of treatment of screen-detected thyroid cancer.

119 es, driven largely by increases in papillary thyroid cancer.

120 gy-associated pathogenesis of differentiated thyroid cancer.

121 ; P < .001; melanoma: R = 0.36; P = .01; and thyroid cancer: R = 0.30; P = .03).

122 and inflammation in papillary and follicular thyroid cancers and the presence of multipotent mesenchy

123 Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P

124 p75(NTR) was overexpressed in anaplastic thyroid cancers compared with papillary and follicular s

125 of an antitumour immune response in advanced thyroid cancers linked to cytotoxic T cells and NK cells

126 ancers, non-Hodgkin lymphomas, and medullary thyroid cancers represent novel indications for the in v

127 f human poorly differentiated and anaplastic thyroid cancers screened by next-generation sequencing u

128 at results in the identification of indolent thyroid cancers, and treatment of these overdiagnosed ca

129 TrkA was detected in 20% of thyroid cancers, compared with none of the benign sample

130 ogy from fine-needle aspiration can identify thyroid cancers, it is unclear if population-based or ta

131 s of human RAS-driven, poorly differentiated thyroid cancers.

132 inical behavior and outcome of patients with thyroid cancers.

133 ours, and a subset of malignant melanoma and thyroid cancers.

134 mmon subsequent malignancies were breast and thyroid cancers.

135 re malignancy that accounts for 1%-2% of all thyroid cancers.

136 se 2 phenotypes is the presence of medullary thyroid carcinoma (MTC).

137 Papillary thyroid carcinoma (PTC), the most frequent thyroid cance

138 13) firmly associated with risk of papillary thyroid carcinoma (PTC).

139 ssion and the oncogenic activation of RET in thyroid carcinoma and describe the involved signal trans

140 ter understanding of the correlation between thyroid carcinoma and LFS, tumor profile data of Brazili

141 els for the evaluation of IDO1 expression in thyroid carcinoma cells and for the study of involved si

142 with a wide variety of tumors; nevertheless, thyroid carcinoma has not been evaluated in this syndrom

143 To determine the frequency of thyroid carcinoma in Brazilian carriers of a founder TP5

144 Here, we describe a novel model of thyroid carcinoma in zebrafish that reveals temporal cha

145 e pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not di

146 stomach carcinoma, and thyroglobulin (TG) in thyroid carcinoma.

147 dine therapy in patients with differentiated thyroid carcinoma.

148 genic RAS mutations are present in 15-30% of thyroid carcinomas.

149 ants cooperated with oncogenic RAS to induce thyroid cell proliferation, pointing to ATXN7 as a previ

150 RNA knockdown of FOXE1 in primary thyroid cells profoundly interferes with the p53 pathway

151 In normal thyroid cells, TGF-beta/SMAD repressed the p27/CDKN1B ge

152 cells while not affecting survival in normal thyroid cells.

153 ty of malignant tumors, including those from thyroid, colon and breast, but its role remains unclear

154 hromosome inactivation has been found in the thyroid condition, Graves' disease, as well as in mother

155 d hormones were measured in a subset without thyroid disease (n=551).

156 o support associations of PBBs and PCBs with thyroid disease and thyroid hormone levels.

157 To determine the association between thyroid disease and uveitis.

158 ith uveitis as the main outcome variable and thyroid disease as the main predictor variable, while ad

159 in thyroid function and the consequences of thyroid disease during pregnancy has rapidly grown in th

160 i population control group, patients who had thyroid disease had a 1.7-fold (95% CI, 1.03-2.80; P = .

161 There were 21 cases of thyroid disease in men [OR=0.69 (95% CI: 0.33); 1.44 for

162 Thyroid disease was common (18% overall; 25% among women

163 Thyroid disease was determined based on International Cl

164 women, all odds ratios (ORs) for PBB-153 and thyroid disease were positive for quintiles above the re

165 itis compared with patients who did not have thyroid disease when controlling for age, sex, race, smo

166 th conditions (including physician-diagnosed thyroid disease), behaviors, and demographics.

167 ncrease in PBB-153 (0.43 ng/mL), the OR (any thyroid disease)=1.12; (95% CI: 0.83, 1.52) (n=105 cases

168 study period, 29 (12.9%) had a diagnosis of thyroid disease, compared with 62 of 896 patients (6.9%)

169 r autoimmune disorders, including autoimmune thyroid disease.

170 associations between serum PBBs and PCBs and thyroid disease.

171 I for diagnostic and therapeutic purposes in thyroid diseases.

172 ction through multiple mechanisms, including thyroid disruption.

173 ts the importance of determining the role of thyroid dysfunction in the onset and progression of mang

174 Thyroid dysfunction is more common in adult patients wit

175 Thyroid dysfunction rates are increased in patients with

176 compared to children born to mothers with no thyroid dysfunction.

177 nganese detoxification and manganese-induced thyroid dysfunction.

178 ng a method to separately derive lung versus thyroid epithelial lineages, as these two cell types eac

179 id hormone biosynthesis and proliferation of thyroid follicular cells and uncovers a mechanism by whi

180 ychlorinated biphenyls (PCBs) and markers of thyroid function among Michigan adults.

181 ain past findings relating familial atypical thyroid function and male homosexuality.

182 Understanding of changes in thyroid function and the consequences of thyroid disease

183 rom prospective cohort studies that measured thyroid function at baseline and assessed incident AF.

184 ion between metabolic syndrome and declining thyroid function remains unclear.

185 ulated and correlated with Tc-99m uptake and thyroid function tests of the patients.

186 Thyroid function was normal, as were 5-hydroxyindoleacet

187 Genetically predicted thyroid function was not associated with IHD (odds ratio

188 mponents of metabolic syndrome and declining thyroid function were also undertaken.

189 To investigate the association of thyroid function with atherosclerosis throughout its spe

190 However, the relationship of thyroid function with manifestations of atherosclerosis

191 However, the functions of GLIS3 in the thyroid gland and the mechanism by which GLIS3 dysfuncti

192 gnificant difference in the ADC value of the thyroid gland between patients and the control group (P=

193 We concluded that ADC values of the thyroid gland can be used to differentiate Graves' disea

194 ism in fetal sheep induced by removal of the thyroid gland caused asymmetric organ growth, increased

195 The mean ADC value of the thyroid gland in Graves' disease was 2.03+/-0.28x10(-3)

196 The mean ADC value of the thyroid gland in patients positively correlated with ser

197 ed in sheep fetuses following removal of the thyroid gland in utero.

198 The thyroid gland secretes primarily tetraiodothyronine (T4)

199 ent diffusion coefficient (ADC) value of the thyroid gland was calculated and correlated with Tc-99m

200 Diffusion-weighted MR imaging of the thyroid gland was performed in patients and controls.

201 erum creatine kinase and aldolase levels and thyroid, hepatic, and renal function.

202 antly worse in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute m

203 Thyroid hormone (T3) affects development and metabolism

204 with both processes taking place when plasma thyroid hormone (T3) levels are high.

205 Thyroid hormone (TH) and TH receptors (TRs) alpha and be

206 mediated I(-) uptake plays a pivotal role in thyroid hormone (TH) biosynthesis.

207 cumulation in the thyroid, the first step in thyroid hormone (TH) biosynthesis.

208 3) is considered to be the primary bioactive thyroid hormone (TH) due to its high affinity for TH nuc

209 ing postnatal day 7-10, when serum levels of thyroid hormone (TH) rise.

210 Inactivating mutations in the thyroid hormone (TH) transporter Monocarboxylate transpo

211 e shortest larval period, highest whole-body thyroid hormone and corticosterone content, and highest

212 ses during metamorphosis point to a role for thyroid hormone and retinoic acid signaling, as well as

213 LIS3 as a key regulator of TSH/TSHR-mediated thyroid hormone biosynthesis and proliferation of thyroi

214 nal activation of several genes required for thyroid hormone biosynthesis, including the iodide trans

215 Hypothyroidism is a common condition of thyroid hormone deficiency, which is readily diagnosed a

216 -tetrabromoethylcyclohexane (beta-TBECH), on thyroid hormone deiodinase (DIO) and sulfotransferase (S

217 Thyroid hormone is critical for normal brain development

218 exposure has been associated with decreased thyroid hormone levels in animals, but human studies are

219 atistical evidence supporting the utility of thyroid hormone levels in prognosis of acute stroke.

220 ssociation between maternal TCS exposure and thyroid hormone levels of mothers and newborns.

221 ome or standardized mean difference (SMD) of thyroid hormone levels with 95% confidence intervals (95

222 ns of PBBs and PCBs with thyroid disease and thyroid hormone levels.

223 d biosynthesis, cholesterol biosynthesis and thyroid hormone metabolic processes.

224 t mediates ligand-independent actions of the thyroid hormone receptor (TR) during development and in

225 We found that the thyroid hormone receptor (TRalpha 3) has a differential

226 ASO-T3 (NAT3) and ApoB-ASO-T3 (AAT3) enhance thyroid hormone receptor activity.

227 Thyroid hormone receptor alpha (THRA) gene mutations, vi

228 The standard treatment is thyroid hormone replacement therapy with levothyroxine.

229 ncreatic beta cell is therefore sensitive to thyroid hormone, insulin and leptin before birth, with p

230 ed the hippocampal expression changes in the thyroid hormone-inactivating enzyme, deiodinase-III (Dio

231 with the TR, in Pax8-KO mice, which make no thyroid hormone.

232 us nonthyroid tissues was-in part-induced by thyroid (hormone)-dependent signaling.

233 ley syndrome patients.SIGNIFICANCE STATEMENT Thyroid hormones (THs) are essential to establish the st

234 ns blood plasma levels of estradiol (E2) and thyroid hormones (TSH, T3t, T4t) were also determined.

235 Previous studies on the association between thyroid hormones and prognosis of acute ischemic stroke

236 Thyroid hormones are also important regulators of fetal

237 gs of this study highlight the importance of thyroid hormones during pregnancy for normal development

238 RATIONALE: Thyroid hormones have been linked with various proathero

239 a-analysis to assess the prognostic value of thyroid hormones in AIS.

240 solated fetal sheep islets studied in vitro, thyroid hormones inhibited beta cell proliferation in a

241 the present study tested the hypotheses that thyroid hormones promote beta cell proliferation in the

242 Thyroid hormones were measured in a subset without thyro

243 metric pigmentation and, via cross-talk with thyroid hormones, in modulating eye migration.

244 Here, we investigate whether thyroid-hormones (TH) and their receptors (TR) coordinat

245 es in pregnant women with normal functioning thyroids (ie, euthyroid) have been associated with sever

246 Perturbation of thyroid iodide uptake is a well-documented side effect o

247 BMP+FGF) that regulate distinct lung- versus thyroid-lineage specification, respectively, from foregu

248 UVmean were both significantly higher in the thyroid, liver, and spleen (P < 0.05) than the values me

249 h-risk sonographic features was specific for thyroid malignancy.

250 singly, Slc30a10 knockouts also had elevated thyroid manganese and developed hypothyroidism.

251 0a10 single knockouts is induced by elevated thyroid manganese, which blocks thyroxine production.

252 ronchi, endocrine glands-like C cells of the thyroid (medullary carcinoma), the parasympathetic and s

253 ; kidney; bladder; brain and nervous system; thyroid; mesothelioma; Hodgkin lymphoma; non-Hodgkin lym

254 ssed the effects of BRAF(V600E) and restored thyroid morphology and hormone synthesis.

255 typic and differentiation characteristics of Thyroid MSCs and PTC MSCs were comparable with bone marr

256 In the thyroid, NIS-mediated I(-) uptake plays a pivotal role i

257 f 288], P < .001) and multinodular goiter or thyroid nodule (40.7% [50 of 123] vs 29.2% [84 of 288],

258 95% CI, 3.49-16.69), multinodular goiter or thyroid nodule (OR, 1.82; 95% CI, 1.01-3.28), and parath

259 idity and mortality, test accuracy to detect thyroid nodules or thyroid cancer, and harms resulting f

260 , neck palpation was not sensitive to detect thyroid nodules.

261 els, thyroid-stimulating hormone levels, and thyroid peroxidase antibodies.

262 FT4), thyroid-stimulating hormone (TSH), and thyroid peroxidase antibody (TPOAb) were obtained from m

263 ial genetic architecture with positivity for thyroid-peroxidase-specific antibody, driven generally b

264 CoR)/silencing mediator of retinoic acid and thyroid receptors (SMRT) corepressor complex.

265 ics and topography during pregnancy could be thyroid related.

266 clinical PET imaging of hNIS expression and thyroid-related disease; it is the first example of in v

267 TH-associated upstream regulators as well as thyroid-related diseases and functions were generated us

268 T/CT imaging of normal mice showed uptake in thyroid, salivary glands (percentage injected dose/g at

269 -TFB in known areas of high hNIS expression (thyroid, salivary glands, and stomach).

270 performed in patients with indications for a thyroid scan to demonstrate the clinical safety and diag

271 The thyroid-selective effect of ICM was also observed in hum

272 from a bitransgenic murine model (Bi-Tg) of thyroid-specific PBF and PTTG overexpression.

273 ns, and FGF signaling, although required for thyroid specification, unexpectedly appears to be dispen

274 sociated with human brittle bone disease and thyroid stimulating hormone receptor hyperactivity.

275 ormone withdrawal (THW) or recombinant human thyroid-stimulating hormone (rhTSH) injections before (1

276 opeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neur

277 ternal serum levels of free thyroxine (FT4), thyroid-stimulating hormone (TSH), and thyroid peroxidas

278 Associations of thyroid-stimulating hormone and free thyroxine with the

279 proximately 50-80%) and profoundly increased thyroid-stimulating hormone levels ( approximately 800-1

280 e interval, 1.68-3.47 per 1 ng/dL) and lower thyroid-stimulating hormone levels (hazard ratio, 0.92;

281 blood cell count, C-reactive protein levels, thyroid-stimulating hormone levels, and thyroid peroxida

282 thyroid, but in states of hyperactivation of thyroid-stimulating hormone receptors (TSHRs), patients

283 id cancer (DTC) may be prepared using either thyroid-stimulating hormone withdrawal (THW) or recombin

284 The 11 analytes included 9 hormones (ie, thyroid-stimulating hormone, total thyroxine, total trii

285 In NIS KO mice, in the thyroid, stomach, and salivary gland, NIS is absent, and

286 shold number of cases defining a high-volume thyroid surgeon is important, as it has implications for

287 a are known to occur after nearly 50% of all thyroid surgeries as a result of accidental disruption o

288 mpromised (n = 27) parathyroid glands during thyroid surgery with an accuracy of 91.5%.

289 for helping reduce hypoparathyroidism after thyroid surgery.

290 tes active iodide (I(-)) accumulation in the thyroid, the first step in thyroid hormone (TH) biosynth

291 at high I(-) concentrations, I(-) enters the thyroid through routes other than NIS.

292 same gene expression pattern analysed in the thyroid tissue of the patient with BOREALIN-p.R114W.

293 ssed in thyroid cancers compared with benign thyroid tissues (P < 0.0001).

294 ify events that cooperate with Hras(G12V) in thyroid tumor development.

295 icating that SOD3 might be a novel player in thyroid tumor stroma.

296 on of mutant Ras is insufficient to initiate thyroid tumorigenesis in murine models, indicating that

297 The thyroid tumors closely phenocopied the histological feat

298 Thyroid tumors found in this population were reviewed wi

299 ention of free iodide in the perturbation of thyroid uptake and suggest a direct and selective effect

300 We demonstrated that ICM reduce thyroid uptake of iodide independently of free iodide.